ArticleScientific reports2017

Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

Cassandra L Pegg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.